News & Updates

The use of rivaroxaban in nonhospitalized patients with symptomatic COVID-19 falls short of reducing the composite endpoint of venous and arterial thrombotic events, hospitalization, and death, according to data from PREVENT-HD*.

P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.

Poor outcomes hound several patients with chronic kidney disease (CKD) who develop intracerebral haemorrhage, reveals a study presented at the recent AAN 2023.

Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.

Use of vitamin D but not calcium supplementation appears effective at preventing multiple sclerosis (MS) in individuals of European descent, suggests a recent study.

Motivational interviewing (MI) in combination with cognitive behavioural therapy (CBT) improves negative symptoms in patients with schizophrenia, reports a study. These symptoms are initially thought of as resistant to any intervention.

The first study to directly compare two disease-modifying agents for Alzheimer’s disease (AD), the phase III TRAILBLAZER-ALZ 4 study shows promising efficacy and safety data on donanemab vs aducanumab for the treatment of early symptomatic AD.

Treatment with zavegepant nasal spray provides pain and symptom relief in patients with migraine, according to a recent US study presented at AAN 2023.